Portfolio companies news

09 November 2016

Miramar Labs, Inc. ® Reports Record Third Quarter 2016 Financial Results

Miramar Labs, Inc., (OTCQB:MRLB), a global aesthetic company, announced today financial results for the third quarter ended September 30, 2016.

08 November 2016

Clearside Biomedical, Inc. Names Rick McElheny as Vice President, Business Development

Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced that  Rick McElheny  has been named Vice President, Business Development.

07 November 2016

Miramar Labs, Inc.® Receives U.S. FDA 510(k) Clearance for Reduction of Odor

Miramar Labs, Inc., (OTCQB:MRLB), a global aesthetic company, announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market for reduction of odor when patients are treated with the miraDry system. miraDry is now the first and only FDA cleared device for the non-invasive treatment of odor..

03 November 2016

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2016 Financial Results

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and other neuropsychiatric disorders, today provided a business update and announced its financial results for the third quarter ended September 30, 2016.

03 November 2016

Celtaxsys Announces Publication of Clinical Trial Results Demonstrating Its Novel Anti-inflammatory Medicine, Oral Acebilustat, Markedly Reduced Lung Inflammation Without Increased Risk of Immunosuppression, in Patients with Cystic Fibrosis (CF)

Celtaxsys, Inc., a clinical stage drug development company advancing therapies for patients with rare inflammatory diseases, announced today the publication of the second paper detailing the results from Phase 1 clinical trials for its flagship drug, acebilustat. Acebilustat is a novel once-daily oral anti-inflammatory drug in development for treatment of cystic fibrosis (CF) and other rare inflammatory diseases. This second paper details the effect of acebilustat on lung and systemic inflammatory biomarkers in a Phase 1B study in adult CF patients.

01 November 2016

Allergan Successfully Completes Tobira Therapeutics Acquisition

Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that it has successfully completed the acquisition of Tobira Therapeutics, Inc. (NASDAQ: TBRA), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases. Allergan acquired Tobira for an upfront payment of $28.35 per share, in cash, and additional Contingent Value Rights (CVRs) that may be payable based on the successful completion of certain development, regulatory and commercial milestones.

28 October 2016

Celtaxsys Announces Publication of Results Demonstrating the Safety, Tolerability and Optimal PK/PD Profile of First-In-Class Anti-Inflammatory Medicine, Oral Acebilustat, in Phase 1 Clinical Trials Including Cystic Fibrosis Patients

Celtaxsys, Inc., a clinical stage drug development company focused on advancing therapies for patients with rare inflammatory diseases, announced today the publication of the first in a series of papers detailing the results from the Phase 1 clinical trials for its flagship drug, acebilustat. Acebilustat is a novel once-daily oral anti-inflammatory drug in development for treatment of cystic fibrosis (CF) and other rare inflammatory diseases. This first paper details pharmacokinetics (PK), pharmacodynamics (PD) and drug-drug interaction results, as well as initial safety and tolerability, from three Phase 1 studies of acebilustat in healthy volunteers and patients with CF.

25 October 2016

Epic Sciences to Contribute to Cancer Moonshot Blood Profiling Atlas

Epic Sciences in collaboration with other industry, academic, and government partners will contribute to the Blood Profiling Atlas pilot of the Cancer Moonshot Initiative championed by Vice President Biden and the White House. The Blood Profiling Atlas seeks to create an open database of results from liquid biopsy tests to accelerate the development of safe and effective blood profiling diagnostics for patient benefit.

20 October 2016

Tobira Therapeutics Announces Late-Breaking Oral Presentation of CENTAUR Phase 2b Trial Results at the American Academy for the Study of Liver Diseases Annual Meeting

Tobira Therapeutics, Inc. (NASDAQ: TBRA), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases, today announced the acceptance of the company’s late breaking abstract as an oral presentation at the American Academy for the Study of Liver Diseases (AASLD) Annual Meeting (the Liver Meeting®), being held in Boston, MA from November 11-15, 2016.

19 October 2016

Allergan and Tobira Therapeutics Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Proposed Acquisition of Tobira

Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Tobira Therapeutics, Inc. (NASDAQ: TBRA), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases, today announced that the U.S. Federal Trade Commission ("FTC") has granted early termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), with respect to Allergan's pending acquisition of Tobira.